Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 5/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19652093 | 0.91 | USP2 (0.42) | USP2CYP3A4HSD11B1CYP2D6CYP2C19 | |
| SCHEMBL18701846 | 0.85 | HSD11B1 (0.50) | USP2CYP3A4HSD11B1CYP2D6CYP2C19 | |
| SCHEMBL18702006 | 0.81 | HSD11B1 (0.59) | USP2CYP3A4HSD11B1CYP2D6CYP2C19 | |
| SCHEMBL18711889 | 0.79 | USP2 (0.49) | USP2CYP3A4CYP2D6CYP2C19HSD17B10 | |
| SCHEMBL22959553 | 0.79 | HSD11B1 (0.46) | USP2CYP3A4HSD11B1CYP2D6CYP2C19 | |
| SCHEMBL18390378 | 0.78 | CYP3A4 (0.49) | USP2CYP3A4CYP2D6CYP2C19HSD17B10 | |
| SCHEMBL3934383 | 0.78 | USP2 (0.47) | USP2CYP3A4CYP2D6CYP2C19HSD17B10 | |
| SCHEMBL23724098 | 0.77 | CYP1A2 (0.47) | CYP3A4HSD11B1CYP2D6CYP2C19EPHX2 | |
| SCHEMBL18701923 | 0.77 | HSD11B1 (0.44) | HSD11B1EPHX2SPR | |
| SCHEMBL18701880 | 0.77 | EPHX2 (0.43) | USP2CYP3A4HSD11B1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963462-B2 | Sepiapterin reductase inhibitors | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2018-05-08 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | USP2 3169/4885CYP3A4 436/4885HSD11B1 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.